Journal article

Chemoimmunotherapy May Overcome the Adverse Prognostic Significance of 11q Deletion in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Apostolia-Maria Tsimberidou, Constantine Tam, Lynne V Abruzzo, Susan O'Brien, William G Wierda, Susan Lerner, Hagop M Kantarjian, Michael J Keating

Cancer | WILEY | Published : 2009

Grants

Funding Acknowledgements

This work is supported in part by a career development award from the American Society of Clinical Oncology to Apostolia-Maria Tsimberidou. Michael J. Kcating receives both honoraria and research support from Bayer Oncology and Genentech. Susan O'Brien receives research support from Genentech, Berlex, Bingen idec, Eli Lily, Novartis, Bristol-Myers-Squlibb, Gerninx, and Gentra; she is a consultant to Genta, Sanofi-Aventis, and Celgene and is on the scientific advisory boards of Geminx, Biogen Idec, and Fli Lily,